Loading
Life sciences · Journal article
Journal of Ovarian Research · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ovarian cancer (OC) is one of the deadliest malignancies among women and is often diagnosed at advanced stages. Chronic inflammation plays a key role in the initiation and progression of this cancer by promoting tumor growth and spread through the continuous activation of signaling pathways such as NF-κB, JAK/STAT, PI3K/AKT, and MAPK. This review examines the relationship between chronic inflammation and OC and analyzes the molecular mechanisms regulated by inflammatory pathways, particularly within the tumor microenvironment. Additionally, the role of immune cells, including tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), in sustaining chronic inflammation and influencing tumor properties is discussed. In the therapeutic domain, emerging opportunities for targeting inflammatory pathways are reviewed, focusing on agents such as bortezomib, ruxolitinib, everolimus, and trametinib. The combination of these targeted therapies with immunotherapy and other treatment strategies is also explored to enhance therapeutic response and overcome drug resistance. Finally, the challenges and limitations of implementing targeted therapies in OC management are examined.